NEW YORK, June 4, 2026, 14:05 EDT
- ImmunityBio shares picked up around 3.0% in afternoon trading. Biotech funds XBI and IBB moved higher too.
- ImmunityBio, Inc. filed a Form 144 on June 4 for a proposed sale of 268,033 common shares valued at roughly $2.95 million. The Form 144 notice comes ahead of specific restricted or control-stock sales.
- ImmunityBio’s latest Anktiva results, FDA review timing for a wider bladder-cancer label, and upcoming investor events next week all remain in focus for investors.
ImmunityBio shares traded higher Thursday afternoon, holding close to $7.40. Investors sifted through new SEC filings while also watching for the latest clinical news on Anktiva, the company’s bladder-cancer immunotherapy.
The stock added 3.0% to $7.395, with a range from $7.07 to $7.47 on the day. Volume came in at around 5.8 million shares. SPDR S&P Biotech ETF was up 2.6% and the iShares Nasdaq Biotechnology ETF climbed 2.1%. The Nasdaq-100 ETF QQQ gave up 0.3%.
ImmunityBio now faces the question of turning Anktiva, its first commercial product, into a broader cancer play. The company posted first-quarter net product revenue of $44.2 million, up 168% from the same period last year. Cash, cash equivalents and marketable securities totaled $380.9 million as of March 31.
SEC records published Thursday weren’t about earnings or a trial update. It was a Form 144, the type companies file before insiders sell restricted or control stock. The document listed a plan to sell 268,033 ImmunityBio common shares on Nasdaq via Charles Schwab, worth $2.946 million total. The filing also said that no shares had been sold from the account over the last three months.
ImmunityBio put out its most recent press release on June 1, saying it showed two posters and had an online publication at the American Society of Clinical Oncology meeting. The presentations looked at advanced non-small cell lung cancer and non-muscle invasive bladder cancer, or NMIBC, a type that hasn’t spread into the muscle of the bladder.
ImmunityBio’s founder and executive chairman Patrick Soon-Shiong said ASCO results gave support for Anktiva-based treatment’s ability to “restore immune function” and “rescue or reinvigorate” response to checkpoint inhibitors—drugs meant to help immune cells spot cancer. Anktiva is described by the company as an IL-15 receptor agonist, meant to stimulate immune cells like natural killer cells, CD4+ and CD8+ T cells. ImmunityBio, Inc.
Bladder cancer is still the main regulatory event ahead. ImmunityBio said on May 19 that the FDA accepted its sBLA for Anktiva with BCG in BCG-unresponsive NMIBC with papillary disease. BCG is a tuberculosis vaccine also used in bladder cancer. The FDA gave a target action date of Jan. 6, 2027, as its decision deadline under the user-fee rules.
ImmunityBio CEO Richard Adcock said in May the company had “strong demand for ANKTIVA” and started the second quarter with “strong cash position, growing revenues.” The company is still running at a loss. First-quarter net loss attributable to common stockholders was $632.8 million, mostly from non-cash fair-value changes in liabilities as the stock climbed. ImmunityBio, Inc.
J&J’s Inlexzo, or TAR-200, got FDA approval in 2025 for high-risk NMIBC after BCG, Reuters said. Merck’s Keytruda is already on label for some high-risk NMIBC patients who don’t respond to BCG. ImmunityBio isn’t shying from the comparison. The company has run a health-economic analysis that puts Anktiva plus BCG up against TAR-200, and it’s also done a separate indirect comparison with pembrolizumab, which is Keytruda’s generic.
Ruchika Talwar, medical director and assistant professor of urologic oncology at Vanderbilt Health, said treatment in BCG-unresponsive NMIBC is about more than response rates. She pointed to “durability, quality of life” and access to sustainable therapy as key factors. The company’s ISPOR analysis reported cost reductions against TAR-200, mostly due to lower drug and administration costs, but noted these indirect models are not a substitute for direct head-to-head trials. ImmunityBio, Inc.
The downside case is still on the table. The FDA might reject the expanded label, ask for extra data, or limit approval to papillary-only disease. Promotional risk is still in focus after Reuters said in March the FDA found a company ad and podcast to be false or misleading. Piper Sandler analyst Edward Tenthoff told Reuters at the time he thought ImmunityBio could “comply with these requests” and said he was “not changing” his Anktiva revenue forecast. Reuters
ImmunityBio put the Goldman Sachs global healthcare conference on its schedule for June 8-10. The company’s annual meeting is set for June 9, and shareholders have until 5 p.m. Pacific time on June 5 to submit questions.
Right now, the stock trades like a commercial-stage biotech: a product on the market, losses still deep, regulator deadlines ahead. Each new Anktiva data point draws attention and every filing gets a close read.
